2,202 Shares in Becton, Dickinson and Company (NYSE:BDX) Acquired by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC acquired a new position in Becton, Dickinson and Company (NYSE:BDX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,202 shares of the medical instruments supplier’s stock, valued at approximately $500,000.

Several other institutional investors and hedge funds also recently bought and sold shares of BDX. Charles Schwab Investment Management Inc. boosted its holdings in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the period. Nordea Investment Management AB boosted its holdings in Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier’s stock worth $647,082,000 after buying an additional 673,568 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in Becton, Dickinson and Company by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after buying an additional 460,440 shares during the period. Vaughan Nelson Investment Management L.P. bought a new position in Becton, Dickinson and Company in the 3rd quarter worth approximately $108,243,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Becton, Dickinson and Company by 62.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock worth $266,974,000 after buying an additional 424,487 shares during the period. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares in the company, valued at $3,807,235. This trade represents a 4.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the transaction, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,844 shares of company stock valued at $2,210,716. Insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $227.62 on Friday. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. The company has a market capitalization of $66.01 billion, a P/E ratio of 38.32, a P/E/G ratio of 1.80 and a beta of 0.40. The company has a fifty day moving average of $231.79 and a 200-day moving average of $234.09.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.